US20030215396A1 - Method for the production of propellant gas-free aerosols from aqueous medicament preparations - Google Patents
Method for the production of propellant gas-free aerosols from aqueous medicament preparations Download PDFInfo
- Publication number
- US20030215396A1 US20030215396A1 US10/417,766 US41776603A US2003215396A1 US 20030215396 A1 US20030215396 A1 US 20030215396A1 US 41776603 A US41776603 A US 41776603A US 2003215396 A1 US2003215396 A1 US 2003215396A1
- Authority
- US
- United States
- Prior art keywords
- pharmaceutical preparation
- preparation according
- active ingredient
- complexing agent
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
Definitions
- the present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols for inhalation.
- nebulisers are, for example, described in PCT Patent Application WO91/14468, herein incorporated by reference. With the nebulisers described here, active ingredients solutions in defined volumes are sprayed through small jets under high pressure, so that inhalable aerosols with a mean particle size of between 3 and 10 micrometers result.
- a further developed embodiment of the aforementioned nebuliser is described in PCT/EP96/04351. The nebuliser portrayed in FIG. 6 carries the trade mark Respimat®.
- cosolvents are those which contain hydroxyl groups or other polar groups, for example alcohols—especially isopropylalcohol, glycols—especially propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
- Cosolvents are suitable for increasing the solubility of adjuvant materials and, if necessary, active ingredients.
- the proportion of dissolved pharmaceutical in the finished pharmaceutical preparation is between 0.001 and 30%—preferably between 0.05 and 3%, especially 0.01 to 2% (weight/volume).
- the maximum concentration of pharmaceutical is dependent on the solubility in solvent and on the dosage required to achieve the desired therapeutical effect.
- All substances which are suitable for application by inhalation and which are soluble in the specified solvent can be used as pharmaceuticals in the new preparations.
- Pharmaceuticals for the treatment of diseases of the respiratory passages are of especial interest. Therefore, of especial interest are betamimetics, anticholinergics, antiallergics, antihistamines and steroids, as well as combinations of these active ingredients.
- the nebuliser described above can feature spraying anomalies when using aqueous pharmaceutical solutions (generally, double distilled or demineralised (ion exchanged) water is used as a solvent). These spraying anomalies represent an alteration of the spraying pattern of the aerosol, with the consequence that in extreme cases an exact dose can no longer be guaranteed to the patient as a result of the altered mean droplet size distribution (alteration to the lung accessible part of the aerosol). These spraying anomalies especially occur when the nebuliser is used at intervals, for example with breaks of approximately 3 or more days between utilisation. It is possible that these spraying anomalies, which in extreme cases can lead to a dysfunction of the nebuliser, are as a result of microscopic deposits in the area of the jet opening.
- aqueous pharmaceutical solutions generally, double distilled or demineralised (ion exchanged) water is used as a solvent.
- aqueous pharmaceutical preparations which are to be sprayed contain a defined effective quantity of a complexing agent, especially of EDTA (ethylenediamine tetraacetic acid) or salts thereof.
- EDTA ethylenediamine tetraacetic acid
- the aqueous pharmaceutical preparations according to the invention contain water as a solvent, but if necessary ethanol can be added to increase the solubility up to 70% (by volume), preferably between 30 and 60% (by volume).
- preservatives especially benzalkonium chloride
- benzalkonium chloride can be added.
- the preferred quantity of preservative, especially benzalkonium chloride, is between 8 and 12 mg/100 ml solution.
- Suitable complexing agents are those which are pharmacologically acceptable, especially those which are already approved by medical regulating authorities.
- EDTA, nitrilotriacetic acid, citric acid and ascorbic acid and their salts are especially suitable.
- the disodium salt of ethylenediaminetetraacetic acid is especially preferred.
- the quantity of complexing agent is selected so that an effective quantity of complexing agent is added to prevent further occurrence of spraying anomalies.
- the effective quantity of the completing agent Na-EDTA is between 10 and 1000 mg/100 ml solution, especially between 10 and 100 mg/100 ml solution.
- the preferred range of the quantity of complexing agent is between 25 and 75 mg/100 ml solution, especially between 25 and 50 mg/100 ml solution.
- the following named compounds can principally be used as active ingredients, singly or in combination, in the aqueous pharmaceutical preparation according to the invention. In individual cases, it may be required to add a higher quantity of ethanol or a solution mediator to improve solubility.
- steroids which can be used as active ingredients in the pharmaceutical preparations according to the invention: Seratrodast Mycophenolate mofetil Pranlukast Zileutone Butixocort Budesonide Deflazacort Fluticasone Promedrol Mometasone furoate Tipredane Beclomethasone, Douglas Icomethasone enbutate Ciclometasone Cloprednol Fluocortin butyl Halometasone Deflazacort Alclometasone Ciclometasone Alisactide Prednicarbate Hydrocortisone-butyrate propionate Tixocortol-pivalate Alclometasone-dipropionate Lotrisone Canesten-HC Deprodone Fluticasone-propionate Methylprednisolone- Halopredone-acetate Aceponate Mometasone Mornetasone-furoate Hydrocortisone-aceponate Mometasone Morneta
- Unused Respimat® nebulisers were used for the test (technical data: volumes of the applied pharmaceutical preparation approximately 15 ⁇ l, pressure approximately 300 bar, 2 streams impacting from two jet openings of size 5 ⁇ 8 ⁇ m). The operation mode for the test is set so that the units are used 5 times, are left to stand for 3 days, and are used again 5 times, this pattern being repeated. 15 units were examined in each series of measurements, the results with regard to spray anomalies are shown in Table 1. TABLE 1 Number of Concentration of nebulisers EDTA in with spray Duration of Test No.
- composition Components in mg/100 ml Fenoterol 833.3 mg Benzalkonium chloride 10.0 mg EDTA* 50.0 mg HCl (ln) ad pH 3.2 Ipatropium bromide 333.3 mg Benzalkonium chloride 10.0 mg EDTA* 50.0 mg HCl (ln) ad pH 3.4
- a concentration range from 10 mg to 20,000 mg/100 ml is conceivable for the active ingredients, depending on the dose per operation and their solubility.
- the specified doses are calculated based on a therapeutically effective single dose of approximately 12 microlitres per operation.
- the active ingredient concentrations of the pharmaceutical preparations can alter when the volume of the individual dose is altered.
- the concentration range for the complexing agents is between 10 and 1000 mg/100 ml (dependent on the pH value of the solution).
- the preferred range is between 25 mg and 100 mg/100 ml.
- the quantity of benzalkonium chloride should be in the range of 8 to 12 mg/100 ml. p
- the solutions are set to a pH of 3.2 to 3.4 with 0.1 or 1N HCl. All concentrations relate to 100 ml of finished active ingredient solution.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.
Description
- The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols for inhalation.
- In the last 20 years, the use of dosage aerosols has become a strong part of the therapy of obstructive lung diseases, especially asthma. Usually, fluorochlorohydro-carbons are used as propellant gases. Following the recognition of the ozone damaging potential of these propellant gases, attempts to develop alternatives have increased. One alternative is the development of nebulisers, where aqueous solutions of pharmacologically active substance are sprayed under high pressure so that a mist of inhalable particles results. The advantage of these nebulisers is that they completely dispense with the use of propellant gases.
- Such nebulisers are, for example, described in PCT Patent Application WO91/14468, herein incorporated by reference. With the nebulisers described here, active ingredients solutions in defined volumes are sprayed through small jets under high pressure, so that inhalable aerosols with a mean particle size of between 3 and 10 micrometers result. A further developed embodiment of the aforementioned nebuliser is described in PCT/EP96/04351. The nebuliser portrayed in FIG. 6 carries the trade mark Respimat®.
- Usually, pharmaceuticals intended for inhalation are dissolved in an aqueous or ethanolic solution, and according to the solution characteristics of the active substances, solvent mixtures of water and ethanol may also be suitable.
- Other components of the solvent are, apart from water and/or ethanol, optionally other cosolvents, and also the pharmaceutical preparation may also additionally contain flavourings and other pharmacological additives. Examples of cosolvents are those which contain hydroxyl groups or other polar groups, for example alcohols—especially isopropylalcohol, glycols—especially propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters. Cosolvents are suitable for increasing the solubility of adjuvant materials and, if necessary, active ingredients.
- The proportion of dissolved pharmaceutical in the finished pharmaceutical preparation is between 0.001 and 30%—preferably between 0.05 and 3%, especially 0.01 to 2% (weight/volume). The maximum concentration of pharmaceutical is dependent on the solubility in solvent and on the dosage required to achieve the desired therapeutical effect.
- All substances which are suitable for application by inhalation and which are soluble in the specified solvent can be used as pharmaceuticals in the new preparations. Pharmaceuticals for the treatment of diseases of the respiratory passages are of especial interest. Therefore, of especial interest are betamimetics, anticholinergics, antiallergics, antihistamines and steroids, as well as combinations of these active ingredients.
- It was found, in a series of examinations, that the nebuliser described above can feature spraying anomalies when using aqueous pharmaceutical solutions (generally, double distilled or demineralised (ion exchanged) water is used as a solvent). These spraying anomalies represent an alteration of the spraying pattern of the aerosol, with the consequence that in extreme cases an exact dose can no longer be guaranteed to the patient as a result of the altered mean droplet size distribution (alteration to the lung accessible part of the aerosol). These spraying anomalies especially occur when the nebuliser is used at intervals, for example with breaks of approximately 3 or more days between utilisation. It is possible that these spraying anomalies, which in extreme cases can lead to a dysfunction of the nebuliser, are as a result of microscopic deposits in the area of the jet opening.
- Surprisingly, it was discovered that these spraying anomalies no longer occur when the aqueous pharmaceutical preparations which are to be sprayed contain a defined effective quantity of a complexing agent, especially of EDTA (ethylenediamine tetraacetic acid) or salts thereof. The aqueous pharmaceutical preparations according to the invention contain water as a solvent, but if necessary ethanol can be added to increase the solubility up to 70% (by volume), preferably between 30 and 60% (by volume).
- Other pharmacological adjuvants such as preservatives, especially benzalkonium chloride, can be added. The preferred quantity of preservative, especially benzalkonium chloride, is between 8 and 12 mg/100 ml solution.
- Suitable complexing agents are those which are pharmacologically acceptable, especially those which are already approved by medical regulating authorities. EDTA, nitrilotriacetic acid, citric acid and ascorbic acid and their salts are especially suitable. The disodium salt of ethylenediaminetetraacetic acid is especially preferred.
- The quantity of complexing agent is selected so that an effective quantity of complexing agent is added to prevent further occurrence of spraying anomalies.
- The effective quantity of the completing agent Na-EDTA is between 10 and 1000 mg/100 ml solution, especially between 10 and 100 mg/100 ml solution. The preferred range of the quantity of complexing agent is between 25 and 75 mg/100 ml solution, especially between 25 and 50 mg/100 ml solution.
- The following named compounds can principally be used as active ingredients, singly or in combination, in the aqueous pharmaceutical preparation according to the invention. In individual cases, it may be required to add a higher quantity of ethanol or a solution mediator to improve solubility.
- Tiotropium bromide, 3-[(hydroxydi-2-thienylacetyl) oxy]-8,8-dimethyl-8-azoniabicyclo[3.2.1]oct-6-ene-bromide
- As betamimetics:
Bambuterol Bitolterol Carbuterol Formoterol Clenbuterol Fenoterol Hexoprenaline Procaterol Ibuterol Pirbuterol Salmeterol Tulobuterol Reproterol Salbutamol Sulfonterol Terbutaline - 1-(2-Fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl) methyl-2-butylamino]ethanol,
- erythro-5′-hydroxy-8′-(1-hydroxy-2-isopropylaminobutyl) -2H-1,4-benzoxazin-3-(4H)-one,
- 1-(4-Amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butyl-amino)ethanol,
- 1-(4-Ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol.
- As anticholinergics:
- Ipratropium bromide
- Oxitropium bromide
- Trospium chloride
- N-β-fluoroethylene nortropine benzylate methobromide
- As steroids:
- Budesonide
- Beclometasone (or the 17,21-dipropionate)
- Dexamethasone-21-isonicotinate
- Flunisolide
- As antiallergics:
- Disodium cromoglycate
- Nedocromil
- Epinastine
- Examples of steroids which can be used as active ingredients in the pharmaceutical preparations according to the invention:
Seratrodast Mycophenolate mofetil Pranlukast Zileutone Butixocort Budesonide Deflazacort Fluticasone Promedrol Mometasone furoate Tipredane Beclomethasone, Douglas Icomethasone enbutate Ciclometasone Cloprednol Fluocortin butyl Halometasone Deflazacort Alclometasone Ciclometasone Alisactide Prednicarbate Hydrocortisone-butyrate propionate Tixocortol-pivalate Alclometasone-dipropionate Lotrisone Canesten-HC Deprodone Fluticasone-propionate Methylprednisolone- Halopredone-acetate Aceponate Mometasone Mornetasone-furoate Hydrocortisone-aceponate Mometasone Ulobetasol-propionate Aminoglutethimide Triamcinolone Hydrocortisone Meprednisone Fluorometholone Dexamethasone Betamethasone Medrysone Fluclorolone acetonide Fluocinolone acetonide Paramethasone-acetate Deprodone Propionate Aristocort-diacetate Fluocinonide Mazipredone Difluprednate Betamethasone valerate Dexamethasone isonicotinate Beclomethasone-Dipropionate Fluocortolone capronate Formocortal Triamcinolone-Hexacetonide Cloprednol Formebolone Clobetasone Endrisone Flunisolide Halcinonide Fluazacort Clobetasol Hydrocortisone-17-Butyrate Diflorasone Fluocortin Amcinonide Betamethasone Dipropionate Cortivazol Betamethasone adamantoate Fluodexane Trilostane Budesonide Clobetasone Demetex Trimacinolon Benetonide - 9-α-chloro-6-α-fluoro-11-β-17-α-dihydroxy-16-α-methyl-3-oxo-1,4-androstadiene-17-β-carboxylic acid-methylester-17-propionate.
- Other especially suitable active ingredients for the production of aqueous pharmaceutical preparations for applications by inhalation are:
- β-Sympatico-mimetics;
- e.g. Fenoterol, Salbutamol, Formoterol, Terbutalin; Anticholinergics;
- e.g. Ipatropium, Oxitropium, Thiotropium;
- Steroids;
- e.g. Beclomethasone dipropionate, Budesonide, Flunisolide;
- Peptides;
- e.g. insulin;
- Pain killers;
- e.g. Fentanyl.
- It is obvious that those pharmacologically acceptable salts will be used which dissolve in the solvent according to the invention if necessary.
- In the following text, the advantage of the pharmaceutical preparation according to the invention will be explained more clearly with Examples.
- As a pharmaceutical solution, Ipratropium bromide solution (c=333 mg/100 ml) with a pH value of 3.4, and the preservative benzalkonium chloride (c=10 mg/100 ml) was used. The tested solutions either contained no EDTA or EDTA in a concentration of c=0.1 mg, 1 mg, 50 mg and 75 mg/100 ml as a disodium salt.
- Unused Respimat® nebulisers were used for the test (technical data: volumes of the applied pharmaceutical preparation approximately 15 μl, pressure approximately 300 bar, 2 streams impacting from two jet openings of size 5×8 μm). The operation mode for the test is set so that the units are used 5 times, are left to stand for 3 days, and are used again 5 times, this pattern being repeated. 15 units were examined in each series of measurements, the results with regard to spray anomalies are shown in Table 1.
TABLE 1 Number of Concentration of nebulisers EDTA in with spray Duration of Test No. mg/100 ml anomalies test in days 1 0 mg/100 ml 2 20 2 0 mg/100 ml 5 9 3 0.1 mg/100 ml 5 6 4 1 mg/100 ml 6 6 5 50 mg/100 ml 0 200 6 50 mg/100 ml 0 200 7 75 mg/100 ml 0 200 8 75 mg/100 ml 0 200 -
Composition Components in mg/100 ml Fenoterol 833.3 mg Benzalkonium chloride 10.0 mg EDTA* 50.0 mg HCl (ln) ad pH 3.2 Ipatropium bromide 333.3 mg Benzalkonium chloride 10.0 mg EDTA* 50.0 mg HCl (ln) ad pH 3.4 - In analogy to the above Examples, the following solutions were produced.
Active Concentration Benzalkonium ingredient mg/100 ml chloride EDTA* Solvent Berotec 104-1.667 10 mg 50 mg Water Atrovent 83-1.333 10 mg 50 mg Water Berodual 41-667 10 mg 50 mg Water (Atrovent) 104-1.667 10 mg 50 mg Water (Berotec) Salbutamol 104-1.667 10 mg 50 mg Water Combivent 167-667 10 mg 50 mg Water (Atrovent) 833-1.667 10 mg 50 mg Water (Salbutamol) Ba 679 Br 4-667 10 mg 50 mg Water (Tiotropium- bromide) BEA 2108 Br 17-833 10 mg 50 mg Water Oxivent 416-1.667 10 mg 50 mg Water - A concentration range from 10 mg to 20,000 mg/100 ml is conceivable for the active ingredients, depending on the dose per operation and their solubility. The specified doses are calculated based on a therapeutically effective single dose of approximately 12 microlitres per operation. The active ingredient concentrations of the pharmaceutical preparations can alter when the volume of the individual dose is altered.
- The concentration range for the complexing agents (for example DiNa-EDTA) is between 10 and 1000 mg/100 ml (dependent on the pH value of the solution). The preferred range is between 25 mg and 100 mg/100 ml.
- The quantity of benzalkonium chloride should be in the range of 8 to 12 mg/100 ml. p The solutions are set to a pH of 3.2 to 3.4 with 0.1 or 1N HCl. All concentrations relate to 100 ml of finished active ingredient solution.
Claims (21)
1. An aqueous pharmaceutical preparation in the form of a solution for the production of propellant-free aerosols for inhalation comprising a pharmacologically active ingredient, characterised in that the pharmaceutical preparation contains a complexing agent.
2. A pharmaceutical preparation according to claim 1 , characterised in that the active ingredient is intended for application by inhalation, especially for the treatment of respiratory passage diseases.
3. A pharmaceutical preparation according to claim 2 , characterised in that the active ingredient is selected from the group betamimetics, anticholinergics, antiallergics and/or antihistamines.
4. A pharmaceutical preparation according to claims 1, 2 or 3, characterised in that the active ingredient is selected from the group
Fenotrol, Ipatropium bromide, Berotec, Atrovent, Berodual, Salbutamol, Combivent, Ba 679 Br, BEA 2108 Br, Oxivent.
5. A pharmaceutical preparation according to any one of claims 1 to 4 , characterised in that the complexing agent is nitrilotriacetic acid, citric acid, ascorbic acid or salts thereof.
6. A pharmaceutical preparation according to any one of claims 1 to 4 , characterised in that the complexing agent is EDTA or a salt thereof.
7. A pharmaceutical preparation according to any one of claims 1 to 6 , characterised in that the concentration of the complexing agent is between 10 and 100 mg/100 ml solution.
8. A pharmaceutical preparation according to claim 7 characterised in that the concentration of the complex former is between 25 and 75 mg/100 ml solution.
9. A pharmaceutical preparation according to one of claims 1 to 8 , characterised in that the adjuvant is a preservative.
10. A pharmaceutical preparation according to claim 9 , characterised in that the preservative is Benzalkonium chloride.
11. A pharmaceutical preparation according to any one of the previous claims, characterised in that the pharmaceutical preparation contains up to 70% (by volume) ethanol.
12. A pharmaceutical preparation according to one of the previous claims, characterised in that it contains the active ingredient in a concentration of 0.001 to 2 g/100 ml solution.
13. A pharmaceutical preparation according to any one of the previous claims, characterised in that it contains pharmacologically acceptable adjuvant and flavouring substances.
14. The use of aqueous pharmaceutical preparations in the production of propellant-free aerosols for inhalation, characterised in that the pharmaceutical preparations contain a complexing agent.
15. The use according to claim 14 , characterised in that the active ingredient is selected from the group Betamimetics, Anticholinergics, Antiallergics and/or antihistamines.
16. The use according to claim 14 or 15, characterised in that the active ingredient is selected from the group
Fenotrol, Ipatropium bromide, Berotec, Atrovent, Berodual, Salbutamol, Combivent, Ba 679 Br, BEA 2108 Br, Oxivent.
17. The use according to any one of claims 14 to 16 , characterised in that the complexing agent is nitriloacetic acid, citric acid, ascorbic acid or a salt thereof.
18. The use according to any one of claims 14 to 16 , characterised in that the complexing agent is EDTA or a salt thereof.
19. The use according to claim 18 , characterised in that the concentration of the complexing agent is between 25 and 75 mg.
20. The use according to any one of claims 14 to 19 , characterised in that the pharmaceutical preparation contains up to 70% (by volume) ethanol.
21. The use according to any one of claims 14 to 20 , characterised in that the pharmaceutical preparation contains active ingredient in a concentration of 0.001 to 2 g/100 ml solution.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/417,766 US20030215396A1 (en) | 1999-09-15 | 2003-04-17 | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
US11/506,128 US7470422B2 (en) | 1996-12-20 | 2006-08-17 | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
US12/338,812 US20090099225A1 (en) | 1996-12-20 | 2008-12-18 | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
US12/413,828 US20090185983A1 (en) | 1996-12-20 | 2009-03-30 | Aqueous medicament preparations for the production of propellant gas-free aerosols |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/331,023 US20010008632A1 (en) | 1996-12-20 | 1997-12-16 | Aqueous medicament preparations for the production of propellent gas-free aerosols |
US10/417,766 US20030215396A1 (en) | 1999-09-15 | 2003-04-17 | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/007062 Continuation WO1998027959A2 (en) | 1996-12-20 | 1997-12-16 | New aqueous medicament preparations for the production of propellent gas-free aerosols |
US09/331,023 Continuation US20010008632A1 (en) | 1996-12-20 | 1997-12-16 | Aqueous medicament preparations for the production of propellent gas-free aerosols |
US09331023 Continuation | 1997-12-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/506,128 Continuation US7470422B2 (en) | 1996-12-20 | 2006-08-17 | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030215396A1 true US20030215396A1 (en) | 2003-11-20 |
Family
ID=29420273
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/417,766 Abandoned US20030215396A1 (en) | 1996-12-20 | 2003-04-17 | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
US11/506,128 Expired - Fee Related US7470422B2 (en) | 1996-12-20 | 2006-08-17 | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/506,128 Expired - Fee Related US7470422B2 (en) | 1996-12-20 | 2006-08-17 | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
Country Status (1)
Country | Link |
---|---|
US (2) | US20030215396A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050288274A1 (en) * | 1999-11-12 | 2005-12-29 | Boehringer Ingelheim Pharma Gmbh | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US20070065366A1 (en) * | 2005-08-01 | 2007-03-22 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation |
EP2034990A2 (en) * | 2006-05-26 | 2009-03-18 | Dey L.P. | Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
WO2016185282A1 (en) * | 2015-05-18 | 2016-11-24 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
US9987260B2 (en) | 2015-05-18 | 2018-06-05 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
US10653683B2 (en) | 2015-05-18 | 2020-05-19 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19653969A1 (en) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | New aqueous pharmaceutical preparation for the production of propellant-free aerosols |
JP5317961B2 (en) * | 2006-05-19 | 2013-10-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Inhalation aerosol formulation containing ipratropium bromide and salbutamol sulfate without propellant |
US20100144784A1 (en) * | 2006-05-19 | 2010-06-10 | Boehringer Ingelheim International Gmbh | Aerosol formulation |
DE102006023770A1 (en) * | 2006-05-20 | 2007-11-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Propellant-free aerosol formulation for inhalation |
US8005549B2 (en) * | 2007-09-13 | 2011-08-23 | Medtronic, Inc. | Medical electrical lead |
EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
EP2662472B1 (en) | 2009-03-31 | 2019-02-27 | Boehringer Ingelheim International Gmbh | Method for coating a surface of a component |
EP3508239B1 (en) | 2009-05-18 | 2020-12-23 | Boehringer Ingelheim International GmbH | Adapter, inhalant apparatus and atomizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
SG181050A1 (en) | 2009-11-25 | 2012-07-30 | Boehringer Ingelheim Int | Nebulizer |
JP5658268B2 (en) | 2009-11-25 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Nebulizer |
WO2011160932A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
WO2012130757A1 (en) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medical device comprising a container |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
WO2013152894A1 (en) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Atomiser with coding means |
WO2015018904A1 (en) | 2013-08-09 | 2015-02-12 | Boehringer Ingelheim International Gmbh | Nebulizer |
PL2835146T3 (en) | 2013-08-09 | 2021-04-06 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10722666B2 (en) | 2014-05-07 | 2020-07-28 | Boehringer Ingelheim International Gmbh | Nebulizer with axially movable and lockable container and indicator |
BR112016023983B1 (en) | 2014-05-07 | 2022-10-18 | Boehringer Ingelheim International Gmbh | CONTAINER FOR A NEBULIZER, NEBULIZER FOR A FLUID AND METHOD FOR CONNECTING A CONTAINER TO AN INDICATOR DEVICE |
WO2015169759A1 (en) | 2014-05-07 | 2015-11-12 | Boehringer Ingelheim International Gmbh | Nebulizer and container |
US10603451B2 (en) | 2014-11-20 | 2020-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Container for an inhaler |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5497944A (en) * | 1990-03-21 | 1996-03-12 | Dmw (Technology) Limited | Atomising devices and methods |
US5964416A (en) * | 1995-10-04 | 1999-10-12 | Boehringer Ingelheim Gmbh | Device for producing high pressure in a fluid in miniature |
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
US6150418A (en) * | 1998-10-17 | 2000-11-21 | Boehringer Ingelheim Pharma Kg | Active substance concentrate with formoterol, suitable for storage |
US6455524B1 (en) * | 1999-03-12 | 2002-09-24 | Boehringer Ingelheim Pharma Kg | Medicament compositions based on anticholinergically-effective compounds and beta-mimetics |
US6491897B1 (en) * | 1995-06-27 | 2002-12-10 | Boehringer Ingelheim Kg | Stable pharmaceutical budesonide preparation for producing propellant-free aerosols |
US20020193392A1 (en) * | 2000-11-13 | 2002-12-19 | Christel Schmelzer | Pharmaceutical compositions based on tiotropium salts of salts of salmeterol |
US20040132761A1 (en) * | 2000-10-31 | 2004-07-08 | Boehringer Ingelheim Pharma Kg | Inhalable formulation of a solution containing a tiotropium salt |
US6890517B2 (en) * | 2000-10-31 | 2005-05-10 | Boehringer Ingelheim Pharma Kg | Inhalable formulation of a solution containing a tiotropium salt |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US497696A (en) * | 1893-05-16 | Karl wenzel | ||
US396673A (en) * | 1889-01-22 | Pedal for velocipedes | ||
JPH0645538B2 (en) | 1987-09-30 | 1994-06-15 | 日本化薬株式会社 | Nitroglycerin spray |
GB8825892D0 (en) | 1988-11-04 | 1988-12-07 | Fisons Plc | Pharmaceutical composition |
EP0489217A1 (en) | 1990-12-05 | 1992-06-10 | Dr. A. Tosi Farmaceutici S.R.L. | Calcitonin compositions for intranasal administration |
JP3207212B2 (en) | 1991-03-01 | 2001-09-10 | 久光製薬株式会社 | Absorption promoter and external preparation containing the same |
JPH0558888A (en) | 1991-09-06 | 1993-03-09 | Kyorin Pharmaceut Co Ltd | Inhalant |
RO117414B1 (en) | 1992-12-09 | 2002-03-29 | Jager Paul D Waterbury | Pharmaceutical composition of gas dispersoid in solution |
BE1007402A5 (en) | 1993-03-26 | 1995-06-06 | Adir | NASAL PHARMACEUTICAL PREPARATIONS WITH progestagen SUBSTANCE. |
DE19620509A1 (en) | 1996-05-22 | 1997-11-27 | Hoechst Ag | Use of non-peptide bradykinin antagonist compounds - to treat chronic fibrogenetic liver disease, (liver cirrhosis and liver fibrosis) and acute liver disease, and to prevent complications |
JPH10130148A (en) | 1996-09-04 | 1998-05-19 | Senju Pharmaceut Co Ltd | Composition for nebulizer |
DE19733651A1 (en) | 1997-08-04 | 1999-02-18 | Boehringer Ingelheim Pharma | Aqueous aerosol preparations containing biologically active marrow molecules and processes for producing corresponding aerosols |
DE19847968A1 (en) | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit. |
US20040019073A1 (en) * | 2002-04-11 | 2004-01-29 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Aerosol formulation for inhalation containing a tiotropium salt |
-
2003
- 2003-04-17 US US10/417,766 patent/US20030215396A1/en not_active Abandoned
-
2006
- 2006-08-17 US US11/506,128 patent/US7470422B2/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5497944A (en) * | 1990-03-21 | 1996-03-12 | Dmw (Technology) Limited | Atomising devices and methods |
US6491897B1 (en) * | 1995-06-27 | 2002-12-10 | Boehringer Ingelheim Kg | Stable pharmaceutical budesonide preparation for producing propellant-free aerosols |
US5964416A (en) * | 1995-10-04 | 1999-10-12 | Boehringer Ingelheim Gmbh | Device for producing high pressure in a fluid in miniature |
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
US6150418A (en) * | 1998-10-17 | 2000-11-21 | Boehringer Ingelheim Pharma Kg | Active substance concentrate with formoterol, suitable for storage |
US6455524B1 (en) * | 1999-03-12 | 2002-09-24 | Boehringer Ingelheim Pharma Kg | Medicament compositions based on anticholinergically-effective compounds and beta-mimetics |
US6630466B2 (en) * | 1999-05-12 | 2003-10-07 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and salmeterol |
US20040132761A1 (en) * | 2000-10-31 | 2004-07-08 | Boehringer Ingelheim Pharma Kg | Inhalable formulation of a solution containing a tiotropium salt |
US6890517B2 (en) * | 2000-10-31 | 2005-05-10 | Boehringer Ingelheim Pharma Kg | Inhalable formulation of a solution containing a tiotropium salt |
US20020193392A1 (en) * | 2000-11-13 | 2002-12-19 | Christel Schmelzer | Pharmaceutical compositions based on tiotropium salts of salts of salmeterol |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090239842A1 (en) * | 1999-11-12 | 2009-09-24 | Volker Trach | Solutions containing epinastin |
US20070185082A1 (en) * | 1999-11-12 | 2007-08-09 | Volker Trach | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US20070197503A1 (en) * | 1999-11-12 | 2007-08-23 | Volker Trach | Solutions containing epinastin |
US20050288274A1 (en) * | 1999-11-12 | 2005-12-29 | Boehringer Ingelheim Pharma Gmbh | Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane |
US20070065366A1 (en) * | 2005-08-01 | 2007-03-22 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation |
US20100143375A1 (en) * | 2006-05-26 | 2010-06-10 | Dey, L.P. | Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
EP2034990A2 (en) * | 2006-05-26 | 2009-03-18 | Dey L.P. | Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
EP2034990A4 (en) * | 2006-05-26 | 2013-03-06 | Dey L P | Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
WO2016185282A1 (en) * | 2015-05-18 | 2016-11-24 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
US9987260B2 (en) | 2015-05-18 | 2018-06-05 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
US10632109B2 (en) | 2015-05-18 | 2020-04-28 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
US10632108B2 (en) | 2015-05-18 | 2020-04-28 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
US10653683B2 (en) | 2015-05-18 | 2020-05-19 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
EA036707B1 (en) * | 2015-05-18 | 2020-12-10 | Гленмарк Спешелти С.А. | Tiotropium inhalation solution for nebulization |
AU2016264961B2 (en) * | 2015-05-18 | 2021-09-09 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
Also Published As
Publication number | Publication date |
---|---|
US7470422B2 (en) | 2008-12-30 |
US20070077207A1 (en) | 2007-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7470422B2 (en) | Method for the production of propellant gas-free aerosols from aqueous medicament preparations | |
AU740543B2 (en) | New aqueous medicament preparations for the production of propellent gas-free aerosols | |
US6491897B1 (en) | Stable pharmaceutical budesonide preparation for producing propellant-free aerosols | |
CZ222599A3 (en) | Pharmaceutical preparation | |
MXPA99005660A (en) | New aqueous medicament preparations for the production of propellent gas-free aerosols | |
SA05260262B1 (en) | Use of aqueos medicament preparations for the production of propellent gas free aerosols | |
AU3257000A (en) | New, stable medicinal compositions for generating propellant-free aerosols |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |